Inhibikase Therapeutics (Nasdaq:IKT) - Stock Price, News & Analysis

IKT Stock Overview

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders.

About the company

IKT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 99.6% below our estimate of its fair value

Risk Analysis

Makes less than USD$1m in revenue ($261K)

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

+ 1 more risk

Inhibikase Therapeutics, Inc. Competitors

Longeveron

NasdaqCM:LGVN

US$13.1m

Finch Therapeutics Group

NasdaqGS:FNCH

US$4.5m

Soligenix

NasdaqCM:SNGX

US$9.0m

Vaccinex

NasdaqCM:VCNX

US$7.9m

Price History & Performance

Summary of all time highs, changes and price drops for Inhibikase Therapeutics
Historical stock prices
Current Share Price	US$1.58
52 Week High	US$4.35
52 Week Low	US$0.79
Beta	1.2
1 Month Change	-28.51%
3 Month Change	-35.77%
1 Year Change	-52.11%
3 Year Change	-95.15%
5 Year Change	n/a
Change since IPO	-97.34%

Recent updates

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06

Inhibikase Therapeutics prices stock offering at $3

Jun 16

Shareholder Returns

	IKT	US Biotechs	US Market
7D	-25.8%	1.5%	1.2%
1Y	-52.1%	1.1%	24.7%

Return vs Industry: IKT underperformed the US Biotechs industry which returned 1.1% over the past year.

Return vs Market: IKT underperformed the US Market which returned 24.7% over the past year.

Price Volatility

Is IKT's price volatile compared to industry and market?
IKT volatility
IKT Average Weekly Movement	16.0%
Biotechs Industry Average Movement	11.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: IKT's share price has been volatile over the past 3 months.

Volatility Over Time: IKT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2008	9	Milton Werner	www.inhibikase.com

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.

Inhibikase Therapeutics, Inc. Fundamentals Summary

How do Inhibikase Therapeutics's earnings and revenue compare to its market cap?
IKT fundamental statistics
Market cap	US$10.23m
Earnings (TTM)	-US$19.03m
Revenue (TTM)	US$260.50k

39.3x

P/S Ratio

-0.5x

P/E Ratio

Is IKT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IKT income statement (TTM)
Revenue	US$260.50k
Cost of Revenue	US$13.62m
Gross Profit	-US$13.36m
Other Expenses	US$5.67m
Earnings	-US$19.03m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.94
Gross Margin	-5,127.75%
Net Profit Margin	-7,304.73%
Debt/Equity Ratio	3.5%

How did IKT perform over the long term?

See historical performance and comparison

IKT Stock Overview

Rewards

Risk Analysis

Inhibikase Therapeutics, Inc. Competitors

NasdaqCM:LGVN

US$13.1m

NasdaqGS:FNCH

US$4.5m

NasdaqCM:SNGX

US$9.0m

NasdaqCM:VCNX

US$7.9m

Price History & Performance

Recent News & Updates

New major risk - Market cap size

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Full year 2023 earnings: EPS misses analyst expectations

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

New major risk - Share price stability

Recent updates

New major risk - Market cap size

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Full year 2023 earnings: EPS misses analyst expectations

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

New major risk - Share price stability

Consensus revenue estimates increase by 44%

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Third quarter 2023 earnings released: US$0.86 loss per share (vs US$1.07 loss in 3Q 2022)

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Consensus revenue estimates increase by 178%, EPS downgraded

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

New major risk - Financial position

Second quarter 2023 earnings released: US$1.11 loss per share (vs US$1.10 loss in 2Q 2022)

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Inhibikase Therapeutics Receives a Letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.26 loss in 1Q 2021)

Inhibikase Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Full year 2021 earnings released: US$0.81 loss per share (vs US$0.35 loss in FY 2020)

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.082 loss in 3Q 2020)

Inhibikase Therapeutics, Inc. Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.052 loss in 2Q 2020)

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell Microcap Value Index

Inhibikase Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Inhibikase Therapeutics prices stock offering at $3